Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration

Ehrenpreis, Eli D.; Deepak, Parakkal; Semer, Rumi; Du, Hongwu

doi:10.1111/j.1463-1318.2011.02679.x

Cited by 22 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After being infected with MTB, the body weight of mice decreased while Kw/Bw increased. This was in consistence with former studies, where a reduction in body weight was followed by an elevation of Kw/Bw in mice with renal injury [26,27]. MTB-infected mice showed increased levels of BUN and Scr, which indicated that renal injury is characterized by higher levels of BUN and Scr.…”

Section: Discussionsupporting

confidence: 89%

Role of ESAT-6 in renal injury by regulating microRNA-155 expression via TLR4/MyD88 signaling pathway in mice with Mycobacterium tuberculosis infection

et al. 2017

View full text Add to dashboard Cite

The study aims to investigate the underlying mechanism involved in the early secretory antigenic target-6 (ESAT-6) in renal injury through regulation of the expression of miR-155 through the oll-like receptor (TLR)-4 (TLR4)/myeloid differentiation factor 88 (MyD88) signaling pathway in Mycobacterium tuberculosis (MTB)-infected mice. Sixty C57BL/6 mice with MTB-induced renal injury were randomly assigned into control, MTB, mimic, inhibitor, inhibitor + ESAT6, and inhibitor + ESAT6 + TAK242 groups. Body weight, the ratio of kidney weight to body weight (Kw/Bw), blood urea nitrogen (BUN), and serum creatinine (Scr) of mice were measured. Flow cytometry was used to detect renal activation in mice. Expressions of miR-155 and ESAT6 were detected by quantitative real-time PCR (qRT-PCR), and Western blotting was used to examine the expressions of ESAT6, TLR4, and MyD88. Expressions of tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), and interferon-γ (IFN-γ) were measured by qRT-PCR and ELISA. Compared with the control group, the BUN and Scr levels as well as the expression levels of miR-155, TLR4, MyD88, TNF-α, IL-17, and IFN-γ increased, while Kw/Bw decreased in the MTB and mimic groups. In comparison with the MTB group, the above indexes except Kw/Bw were elevated in the mimic group, but were reduced in the inhibitor group, while the Kw/Bw dropped in the mimic group but increased in the inhibitor group. Compared with the inhibitor group, the Kw/Bw decreased while the rest of the indexes increased in the inhibitor + ESAT6 group. ESAT6 may induce renal injury by promoting miR-155 expression through the TLR-4/MyD88 signaling pathway in MTB-infected mice.

show abstract

Section: Discussionsupporting

confidence: 89%

Role of ESAT-6 in renal injury by regulating microRNA-155 expression via TLR4/MyD88 signaling pathway in mice with Mycobacterium tuberculosis infection

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A possible explanation for the asymmetric sex distribution is that women have lower BMIs than do men, but the OSP dose is usually the same [61,104]. However, dosage alone is not completely responsible for this phenomenon.…”

Section: Age Gender and Body Constitutionmentioning

confidence: 84%

“…According to other studies, females and/or smaller and leaner subjects, of both sexes, were at greater risk for developing AKI after OSP than average males [32,[102][103][104].…”

Section: Age Gender and Body Constitutionmentioning

confidence: 98%

Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others

Hoffmanová¹,

Kraml²,

Andĕl³

2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Because of safety concerns, sodium phosphate purgatives are not recommended for routine bowel cleansing. Despite some serious and even fatal adverse events associated with these drugs when used with at-risk patients, available data suggest that administration of sodium phosphate purgatives is relatively safe in nonrisk individuals(i.e., in adequately hydrated, otherwise healthy adults, younger than 55 years with evidence of normal renal function).

show abstract

“…El estudio retrospectivo de la doctora Ehrenpreis y colaboradores, realizado a partir de la base de datos de eventos adversos de la Food and Drug Administration (FDA), desde 2004 hasta 2009, demostró que la tableta de fosfato de sodio se asocia a eventos de lesión renal, más frecuentemente en mujeres con un promedio de peso más bajo de lo normal (68.57 ± 1.78 kg) 6 .…”

Section: Ce Dfunclassified

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Pineda¹,

Molano²,

Flórez³

et al. 2016

acnef

View full text Add to dashboard Cite

Rev. Colomb. Nefrol. 2016; 3(1): 52 -57 Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado. Reporte de un caso 52Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado.Reporte de un casoRoberto Pineda 1 , Alejandra Molano 2 , Adriana Flórez 3 , Roberto D`Achiardi 2 , Benjamín Wancjer 2 ResumenLa nefropatía por fosfato de sodio es una forma de lesión renal que ocurre posterior al uso de laxantes que contienen fosfato de sodio. Puede presentarse de manera aguda o crónica según el tiempo de utilización de dichos medicamentos utilizados para la preparación colónica. La forma aguda puede resolverse con un adecuado tratamiento, pero la forma crónica puede causar daño renal irreversible. Este caso se trata de una paciente con trasplante renal, en seguimiento en la Fundación Cardioinfantil en Bogotá, Colombia, en quien se utilizó fosfato de sodio para una preparación de colonoscopia y se presentó a nuestro servicio con una lesión renal aguda.Palabras clave: Enfermedad renal crónica, nefropatía por fosfato de sodio, diagnóstico (fuente DeCS). Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report AbstractSodium phosphate nephropathy is a form of renal injury that occurs following the use of laxatives containing sodium phosphate, which can present acutely or chronically after the administration of these drugs used in colonic preparation for colonoscopy. The acute form can resolve with adequate treatment, but the chronic form may cause irreversible kidney damage. The case we report is about a kidney transplantantion patient in whom sodium phosphate was used for colonoscopy preparation debuting with acute kidney injury.

show abstract

Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration

Abstract: Renal adverse drug reactions from sodium phosphate tablets are more common in women with a mean body weight lower than the national average weight.

Cited by 22 publications

References 28 publications

Role of ESAT-6 in renal injury by regulating microRNA-155 expression via TLR4/MyD88 signaling pathway in mice with Mycobacterium tuberculosis infection

Role of ESAT-6 in renal injury by regulating microRNA-155 expression via TLR4/MyD88 signaling pathway in mice with Mycobacterium tuberculosis infection

Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Contact Info

Product

Resources

About